Musculoskeletal Disorders
Gain touts positive Phase I results for Parkinson’s therapy
Gain Therapeutics’ GT-02287 was found to be safe and tolerable in the Phase I trial of the therapy in healthy…
Edgewise reports data from trial of muscular dystrophy drug
US-based biotechnology company Edgewise Therapeutics has reported positive two-year topline data from the ARCH clinical trial of sevasemten (EDG-5506) in…
Atamyo obtains clearance for muscular dystrophy gene therapy trial in Europe
Atamyo Therapeutics has received regulatory clearance in Europe to initiate a Phase Ib clinical trial for its gene therapy, ATA-200,…
NMD Pharma gets FDA IND clearance for Phase IIb gMG treatment trial
NMD Pharma has secured clearance for an Investigational New Drug (IND) application from the US Food and Drug Administration to…
Avidity accelerates DM1 Phase III trial on the heels of further positive data
Avidity Biosciences has accelerated the initiation of its Phase III trial in myotonic dystrophy type 1 (DM1) after announcing further…
J&J touts success of nipocalimab in two rare disease trials
Johnson & Johnson (J&J) has announced positive topline results for nipocalimab in two rare disease indications - generalised myasthenia gravis…
Rise Therapeutics begins rheumatoid arthritis therapy trial
US-based biotechnology company Rise Therapeutics has enrolled the first subject in its Phase I clinical trial of R-2487, a new…
Sarepta begins screening in muscular dystrophy gene therapy trial
Sarepta Therapeutics has commenced subject screening for its Phase III EMERGENE clinical trial (Study SRP-9003-301) of investigational gene therapy SRP-9003…
Avenue concludes subject enrolment in SBMA treatment trial
Avenue Therapeutics has completed subject enrolment in the Phase Ib/IIa clinical trial of its new drug candidate, AJ201, to treat…
Lynk commences Phase III rheumatoid arthritis drug trial
Lynk Pharmaceuticals has dosed the first subject in a Phase Ⅲ clinical trial of its JAK1 inhibitor, LNK01001, to treat…
